India’s Pricing Authority Cuts Prices On Two Sanofi Insulin Products
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's pharmaceutical pricing watchdog, the National Pharmaceutical Pricing Authority, has increased prices of 186 formulation brands while slashing prices of Lantus/Solostar (insulin glargine injection) and monocomponent insulin, the two key insulin drugs from French drug maker Sanofi-Aventis, the NPPA announced Aug. 7